Details
| Stereochemistry | RACEMIC |
| Molecular Formula | C16H23NO2.ClH |
| Molecular Weight | 297.82 |
| Optical Activity | ( + / - ) |
| Defined Stereocenters | 0 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
Cl.CCOC(=O)C1(CCCN(C)CC1)C2=CC=CC=C2
InChI
InChIKey=XHRYXPJUXHWWJD-UHFFFAOYSA-N
InChI=1S/C16H23NO2.ClH/c1-3-19-15(18)16(14-8-5-4-6-9-14)10-7-12-17(2)13-11-16;/h4-6,8-9H,3,7,10-13H2,1-2H3;1H
| Molecular Formula | ClH |
| Molecular Weight | 36.461 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
| Molecular Formula | C16H23NO2 |
| Molecular Weight | 261.3593 |
| Charge | 0 |
| Count |
|
| Stereochemistry | RACEMIC |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 1 |
| E/Z Centers | 0 |
| Optical Activity | ( + / - ) |
Ethoheptazine is an analgesic, which belongs to the proheptazine group. It was used either alone (Zactane trade name) or in combination with meprobamate and aspirin (Equagesic) for the pain relief in patients with headache or musculoskeletal disorders. Currently all mediactions containing ethoheptazine are withdrawn from the market. The exact target of ethoheptazine is unknow, but it is believed that it may have modulatory effect on opioid receptors.
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: CHEMBL2095181 |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Palliative | EQUAGESIC Approved UseEquagesic is possibly effective in the treatment of pain accompained by tension and anxiety in patients with musculoskeletal disease or tension headache. |
|||
| Primary | EQUAGESIC Approved UseEquagesic is possibly effective in the treatment of pain accompained by tension and anxiety in patients with musculoskeletal disease or tension headache. |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Methods in evaluating ethoheptazine and ethoheptazine combined with aspirin. | 1958 Apr 12 |
|
| Treatment of musculoskeletal pain and associated anxiety with an ethoheptazine-aspirin-meprobamate combination (equagesic): a controlled study. | 1974 Sep |
|
| Effects of propoxyphene, ethoheptazine, and azabicyclane on schedule-controlled responding: attenuation by pentobarbital but not naloxone. | 1979 |
Patents
| Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 08:53:13 GMT 2023
by
admin
on
Sat Dec 16 08:53:13 GMT 2023
|
| Record UNII |
8KYO8O8JNO
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Code | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
DTXSID5048762
Created by
admin on Sat Dec 16 08:53:13 GMT 2023 , Edited by admin on Sat Dec 16 08:53:13 GMT 2023
|
PRIMARY | |||
|
23616254
Created by
admin on Sat Dec 16 08:53:13 GMT 2023 , Edited by admin on Sat Dec 16 08:53:13 GMT 2023
|
PRIMARY | |||
|
m1138
Created by
admin on Sat Dec 16 08:53:13 GMT 2023 , Edited by admin on Sat Dec 16 08:53:13 GMT 2023
|
PRIMARY | Merck Index | ||
|
5982-61-6
Created by
admin on Sat Dec 16 08:53:13 GMT 2023 , Edited by admin on Sat Dec 16 08:53:13 GMT 2023
|
PRIMARY | |||
|
8KYO8O8JNO
Created by
admin on Sat Dec 16 08:53:13 GMT 2023 , Edited by admin on Sat Dec 16 08:53:13 GMT 2023
|
PRIMARY | |||
|
DBSALT002450
Created by
admin on Sat Dec 16 08:53:13 GMT 2023 , Edited by admin on Sat Dec 16 08:53:13 GMT 2023
|
PRIMARY | |||
|
400484
Created by
admin on Sat Dec 16 08:53:13 GMT 2023 , Edited by admin on Sat Dec 16 08:53:13 GMT 2023
|
PRIMARY |